EQT Agrees to Acquire QIAGEN for $10.78 Billion

Has EQT completed the acquisition of QIAGEN?

No. On October 21, 2026, QIAGEN signed a business combination agreement supporting a cash takeover offer of €46.50 per share. Completion is expected in mid 2027, subject to a minimum acceptance threshold of 50% of outstanding shares plus one share, shareholder resolutions and regulatory clearances.

Orbitrum Investor Impact

Why does the acquisition matter for investors?

The deal offers QIAGEN shareholders a defined cash consideration while giving the company an opportunity to pursue long term investments under private ownership. The agreed enterprise value is approximately €10.8 billion, equivalent to about $12.1 billion including approximately $1.1 billion in net debt.

What does the deal mean for QIAGEN shareholders?

The €46.50 per share offer represents a 40.3% premium to QIAGEN's unaffected share price on July 8, 2026, before takeover interest was reported. If the transaction closes and the planned post closing measures are implemented, QIAGEN's New York Stock Exchange and Frankfurt listings will be terminated.

Why has QIAGEN suspended its 2026 financial outlook?

QIAGEN suspended its full year 2026 outlook while the takeover is pending. Its preliminary third quarter results reported net sales of $548 million and adjusted diluted earnings per share of $0.65, but the company has not provided its previous full year guidance for investors to use.

What happens next in the QIAGEN takeover?

The bidder must publish the formal offer documents after the required German regulatory clearance and file the relevant United States tender offer materials. The transaction is expected to close in mid 2027 if the acceptance threshold, shareholder approvals and required regulatory conditions are satisfied.